The New Hampshire House Special Committee on COVID Response Efficacy convened on October 25, 2024, to discuss critical findings related to COVID-19 vaccines and their implications for public health. The meeting highlighted concerns regarding the long-term effects of mRNA vaccines, particularly in relation to immune responses.

One of the primary topics addressed was the potential for individuals who have received multiple doses of mRNA vaccines to produce a type of antibody known as IgG4. This antibody is associated with immune tolerance, which could lead to a reduced immune response to various pathogens. Experts expressed concern that this phenomenon might compromise the body's ability to respond effectively to infections, including COVID-19 itself.

A representative raised questions about the implications of IgG4 production, noting that while immune tolerance can be beneficial in some contexts, it may pose risks when dealing with pathogens that cause significant health issues. The discussion referenced a study indicating that the immune response to COVID-19 could be uniquely affected by the virus's spike protein, potentially leading to a state of immune compromise.

The committee also examined the results of the original Pfizer vaccine trial, which involved 40,000 participants. Concerns were raised about the statistical significance of adverse events reported during the trial, including cardiovascular issues. The discussion suggested that the limited number of COVID cases observed during the trial may not provide a comprehensive understanding of the vaccine's efficacy and safety.

Overall, the meeting underscored the need for ongoing research into the long-term effects of COVID-19 vaccines, particularly regarding immune responses and potential health risks. The committee's findings may influence future public health policies and vaccine recommendations as the state continues to navigate the pandemic's aftermath.